clinical trial · NCT02340988
Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects
Melinta Therapeutics, Inc.·phase1·completed·n = 36
HealthySingle-Dose IV Oritavancin Diphosphate and WarfarinSingle-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose
brief summary
The purpose of this study is to assess the drug interaction potential and time course of the effect of oritavancin on warfarin pharmacokinetics in an open label, single arm manner.
started
Apr 1, 2015
primary completion
Sep 1, 2015
completion
Sep 1, 2015
last updated
Dec 19, 2023
official title
An Open-Label Study to Assess the Drug-Drug Interaction Potential of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol